Blog
RSS FeedPosted by Michael Wonder on 09 Apr 2024
ViiV Healthcare announces US FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
8 April 2024 - Dovato is now the first and only oral, two drug, single-tablet regimen available for people aged 12 ...
Posted by Michael Wonder on 02 Apr 2024
Relugolix–estradiol–norethisterone acetate for the treatment of patients with pain associated with endometriosis
28 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 25 Mar 2024
US FDA approves Opsynvi (macitentan and tadalafil) as the first and only once daily single tablet combination therapy for patients with pulmonary arterial hypertension
22 March 2024 - Approval is based on the results from the pivotal Phase 3 A DUE study, which met ...
Posted by Michael Wonder on 24 Feb 2024
Venatorx and Melinta provide update on status of US new drug application for cefepime-taniborbactam
23 February 2024 - No clinical safety or efficacy issues identified. ...
Posted by Michael Wonder on 22 Feb 2024
TGA approves new medication for treatment of endometriosis symptoms
23 February 2024 - Australian drug regulator gives company green light for tablet – although it won’t be subsidised by Pharmaceutical ...
Posted by Michael Wonder on 10 Feb 2024
AbbVie's Vyalev (foslevodopa/foscarbidopa solution) available for the treatment of advanced Parkinson's disease in Canada
8 February 2024 - In clinical trials, patients taking Vyalev achieved the primary endpoint of a reduction in motor fluctuations ...
Posted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 23 Jan 2024
Remdesivir and the combination of tixagevimab and cilgavimab for the treatment of patients with COVID-19 disease
18 January 2024 - NICE has published additional draft guidance on the use of remdesivir and the combination of tixagevimab ...
Posted by Michael Wonder on 21 Jan 2024
Advanced melanoma treatment to be added to Pharmaceutical Benefits Scheme
21 January 2024 - Treatment for advanced melanoma is set to become cheaper under the Pharmaceutical Benefits Scheme in the ...
Posted by Michael Wonder on 14 Jan 2024
1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid
11 January 2024 - A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be ...
Posted by Michael Wonder on 29 Dec 2023
Opdualag licensed for patients with advanced melanoma
27 December 2023 - The MHRA has today approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of ...
Posted by Michael Wonder on 03 Dec 2023
Duchesnay is seeking Health Canada approval for a segesterone acetate/ethinyl estradiol contraceptive vaginal system, a new option for women
30 November 2023 - Duchesnay has recently filed a new drug submission to Health Canada for its segesterone acetate/ethinyl estradiol slow ...
Posted by Michael Wonder on 29 Nov 2023
Karuna Therapeutics announces US FDA accepts new drug application for KarXT for the treatment of schizophrenia
29 November 2023 - PDUFA action date is 26 September 2024. ...
Posted by Michael Wonder on 29 Nov 2023
Foslevodopa with foscarbidopa for the treatment of patients with advanced Parkinson’s with motor symptoms
29 November 2023 - NICE has published final evidence-based recommendations on the use of foslevodopa with foscarbidopa (Produodopa) for the ...